Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

被引：3
|
作者：
Scherpereel, Arnaud
Mazieres, Julien
Greillier, Laurent
Do, Pascal
Bylicki, Olivier
Monnet, Isabelle
Corre, Romain
Audigier-Valette, Clarisse
Locatelli-Sanchez, Myriam
Molinier, Olivier
Thiberville, Luc
Urban, Thierry
Ligeza-Poisson, Catherine
Planchard, David
Amour, Elodie
Morin, Franck
Denis
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8507
引用
收藏
页数：6
相关论文
共 34 条
  • [1] Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
    Scherpereel, Arnaud
    Mazieres, Julien
    Greillier, Laurent
    Do, Pascal
    Bylicki, Olivier
    Monnet, Isabelle
    Corre, Romain
    Audigier-Valette, Clarisse
    Locatelli-Sanchez, Myriam
    Molinier, Olivier
    Thiberville, Luc
    Urban, Thierry
    Ligeza-poisson, Catherine
    Planchard, David
    Amour, Elodie
    Morin, Franck
    Moro-Sibilot, Denis
    Zalcman, Gerard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [2] Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial
    Zalcman, G.
    Mazieres, J.
    Greillier, L.
    Lantuejoul, S.
    Do, P.
    Bylicki, O.
    Monnet, I.
    Corre, R.
    Audigier-Valette, C.
    Locatelli-Sanchez, M.
    Molinier, O.
    Thiberville, L.
    Urban, T.
    Planchard, D.
    Ligeza-Poisson, C.
    Amour, E.
    Morin, F.
    Moro-Sibilot, D.
    Scherpereel, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
    Zalcman, G.
    Mazieres, J.
    Greillier, L.
    Brosseau, S.
    Lantuejoul, S.
    Do, P.
    Bylicki, O.
    Monnet, I.
    Corre, R.
    Audigier-Valette, C.
    Locatelli-Sanchez, M.
    Molinier, O.
    Guisier, F.
    Urban, T.
    Planchard, D.
    Ligeza-Poisson, C.
    Amour, E.
    Morin, F.
    Moro-Sibilot, D.
    Scherpereel, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 747 - 747
  • [4] Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
    Scherpereel, Arnaud
    Mazieres, Julien
    Greillier, Laurent
    Lantuejoul, Sylvie
    Do, Pascal
    Bylicki, Olivier
    Monnet, Isabelle
    Corre, Romain
    Audigier-Valette, Clarisse
    Locatelli-Sanchez, Myriam
    Molinier, Olivier
    Guisier, Florian
    Urban, Thierry
    Ligeza-Poisson, Catherine
    Planchard, David
    Amour, Elodie
    Morin, Franck
    Moro-Sibilot, Denis
    Zalcman, Gerard
    LANCET ONCOLOGY, 2019, 20 (02): : 239 - 253
  • [5] Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial (vol 20, pg 239, 2019)
    Scherpereel, A.
    Mazieres, J.
    Greillier, L.
    LANCET ONCOLOGY, 2019, 20 (03): : E132 - E132
  • [6] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
    Scherpereel, A.
    Antonia, S.
    Bautista, Y.
    Grossi, F.
    Kowalski, D.
    Zalcman, G.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mansfield, A.
    Popat, S.
    Sun, X.
    Padilla, B.
    Aanur, P.
    Daumont, M.
    Bennett, B.
    McKenna, M.
    Baas, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1441 - S1441
  • [7] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
    Bischoff, H.
    Scherpereel, A.
    Antonia, S.
    Bautista, Y.
    Grossi, F.
    Kowalski, D.
    Zalcman, G.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mans-Field, A.
    Popat, S.
    Sun, X.
    Padilla, B.
    Aanur, P.
    Daumont, M.
    Bennett, B.
    McKenna, M.
    Baas, P.
    PNEUMOLOGIE, 2021, 75 : S17 - S17
  • [8] Evaluation of flat dosing for nivolumab (NIVO) plus ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)
    Tsao, A. S.
    Baas, P.
    Nowak, A.
    Zalcman, G.
    Fujimoto, N.
    Peters, S.
    Baudelet, C.
    Aanur, P.
    Osawa, M.
    Tendolkar, A.
    Feng, Y.
    Sheng, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1445 - S1445
  • [9] First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
    Peters, S.
    Scherpereel, A.
    Cornelissen, R.
    Oulkhouir, Y.
    Greillier, L.
    Kaplan, M. A.
    Talbot, T.
    Monnet, I.
    Hiret, S.
    Baas, P.
    Nowak, A. K.
    Fujimoto, N.
    Tsao, A. S.
    Mansfield, A. S.
    Popat, S.
    Zhang, X.
    Hu, N.
    Balli, D.
    Sanzari, J.
    Zalcman, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1341 - S1342
  • [10] Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
    Nakano, T.
    Okada, M.
    Kijima, T.
    Aoe, K.
    Kato, T.
    Fujimoto, N.
    Nakagawa, K.
    Takeda, Y.
    Hida, T.
    Kanai, K.
    Imamura, F.
    Oizumi, S.
    Takahashi, T.
    Takenoyama, M.
    Tanaka, H.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S338 - S338
1234